Volume 32, Number 4—April 2026
Research
Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016–2021
Figure 2

Figure 2. VCD and laboratory confirmed chikungunya incidence by temporospatial characteristics, Brazil, 2016–2021. Incidence per 100 person-years of VCD is shown regardless of serotype (A), VCD by DENV serotypes DENV-1 and DENV-2 (B), and laboratory-confirmed chikungunya (C) among participants in the placebo arm of the DEN-03-IB trial of a live attenuated tetravalent dengue vaccine, Butantan-DV, by temporospatial characteristic (geographic region and study year). Points represent incidence estimates and error bars represent 95% CIs. Dashed lines represent the overall incidence per 100 person-years and shaded areas around the dashed lines represent 95% CIs for the overall incidence estimates. CW, Center-West; DENV, dengue virus; N, North; NE, Northeast; S, South; SE, Southeast; VCD, virologically confirmed dengue.
1Preliminary results from this study were presented at the American Society for Tropical Medicine and Hygiene annual meeting; November 13–17, 2024; New Orleans, Louisiana, USA.